Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 for negative symptoms of schizophrenia
2021-001352-33Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing AVP-786 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 15 in PANSS Marder negative factors score. Started Jul 2021; status: completed.
02
Drugs
deudextromethorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2021-001352-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001352-33.